rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    OBIO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
      Nov 17Yahoo FinanceOBIO
      Orchestra BioMed stock price target raised to $12 by BTIG on therapy potential
      Nov 13Investing.comOBIO
      Orchestra Biomed Holdings earnings beat by $0.10, revenue fell short of estimates
      Nov 11Investing.comOBIO
      Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates

      Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +25.00% and -17.27%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 10Yahoo FinanceOBIO
      Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
      Nov 10Yahoo FinanceOBIO
      Orchestra BioMed launches public offering of common stock
      Nov 5Investing.comOBIO
      Orchestra BioMed Announces Proposed Public Offering
      Nov 5Yahoo FinanceOBIO
      Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
      Oct 29Yahoo FinanceOBIO
      Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
      Oct 22Yahoo FinanceOBIO
      Piper Sandler reiterates Orchestra BioMed stock rating on AVIM trial
      Oct 15Investing.comOBIO
      Orchestra BioMed Stock Has A Clearer Trial Timeline But A Demanding Valuation (OBIO)
      Oct 15Seeking AlphaOBIO
      H.C. Wainwright reiterates Orchestra BioMed stock rating on trial enrollment
      Oct 5Investing.comOBIO
      Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Regeneron (REGN)

      Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailOBIOREGN
      Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy

      330 patients randomized as of September 30, 2026, surpassing full trial enrollment targetCompany reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 Data expected to support future marketing application submissions by Medtronic to the FDA and other global regulatory agencies NEW HOPE, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or

      Oct 1Yahoo FinanceOBIO
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Natera Inc (NTRA-Q) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailOBIOCRL
      Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?

      Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

      Sep 21Yahoo FinanceOBIO
      Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

      Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyondNEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced

      Sep 16Yahoo FinanceOBIO
      Orchestra BioMed receives $6.1m milestone from Vivasure deal
      Sep 15Investing.comOBIO
      Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of Vivasure
      Sep 15Yahoo FinanceOBIOHAE
      Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
      Sep 15Yahoo FinanceOBIO
      B. Riley Adjusts Orchestra BioMed Price Target to $11 From $10, Maintains Buy Rating

      Orchestra BioMed Holdings (OBIO) has an average rating of buy and mean price target of $12, accordin

      Sep 15Yahoo FinanceOBIO
      Orchestra BioMed at Wells Fargo: partnership model in focus
      Sep 10Investing.comOBIOWFC
      These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?
      Sep 10Yahoo FinanceLFSTOBIO
      Crude Oil Surges 6%; Macy’s Shares Fall After Q2 Results
      Sep 10BenzingaOBIOM
      Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday
      Sep 10BenzingaAVAVCLOVOBIO
      Orchestra BioMed Shares Rise After BTIG Upgrade

      Orchestra BioMed Holdings (OBIO) shares were up about 10% in Thursday trading after BTIG upgraded th

      Sep 10Yahoo FinanceOBIO
      BTIG upgrades Orchestra BioMed stock rating on trial progress
      Sep 10Investing.comOBIO
      BTIG Upgrades Orchestra BioMed to Buy From Neutral, Price Target is $10

      Orchestra BioMed Holdings (OBIO) has an average rating of buy and mean price target of $12, accordin

      Sep 10Yahoo FinanceOBIO
      Orchestra BioMed CEO David Hochman buys $47,900 in common stock
      Sep 8Investing.comOBIO
      Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Sep 2Yahoo FinanceOBIO
      Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
      Aug 27Yahoo FinanceOBIO

      This is the newest page. Registered accounts read further back.